Safety and Efficacy of the Histone Deacetylase Inhibitor Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir (CHARTER)

Trial Profile

Safety and Efficacy of the Histone Deacetylase Inhibitor Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir (CHARTER)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs Tucidinostat (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Acronyms CHARTER
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Sep 2016 Status changed from recruiting to completed.
    • 31 Aug 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top